SGO Endorses Updated CAP Protocol for Biomarker Testing in Gynecologic Carcinomas

The Society of Gynecologic Oncology (SGO) is proud to endorse the College of American Pathologists (CAP) Protocol for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of Gynecologic Origin.

The updated protocol incorporates the latest evidence and advances in biomarker testing to promote standardized pathology reporting and support personalized treatment decisions across the spectrum of gynecologic cancers. By providing clear, evidence-based recommendations for reporting clinically significant biomarkers, the protocol helps ensure pathologists and multidisciplinary care teams have the information needed to guide treatment selection and clinical trial eligibility, and deliver high-quality, patient-centered care. By providing clear, evidence-based recommendations for reporting clinically significant biomarkers, the protocol helps ensure pathologists and multidisciplinary care teams consistently have the information needed to guide treatment selection and clinical trial eligibility, and deliver high-quality, patient-centered care. SGO’s endorsement reflects the Society’s ongoing commitment to advancing evidence-based practice and improving outcomes for individuals with gynecologic cancers.

Read the full article to learn more about the updated CAP protocol and the evidence supporting these recommendations.